{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:59:28Z","timestamp":1784959168108,"version":"3.55.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Targeting the Janus kinase (JAK) signaling pathway is a new way to treat inflammatory bowel disease (IBD). This network meta-analysis aimed to compare the efficacy and safety of various JAK inhibitors, including brepocitinib, filgotinib, ivarmacitinib, peficitinib, ritlecitinib, tofacitinib, and upadacitinib, in patients with IBD. The analysis included patients with both Crohn\u2019s disease (CD) and ulcerative colitis (UC). We systematically searched PubMed, Embase, the Cochrane Library, and the Web of Science for randomized controlled trials evaluating JAK inhibitors in patients with CD or UC up to 4 May 2024. A pooled analysis of UC and CD was performed. The primary outcome was clinical remission. Secondary outcomes included clinical response, endoscopic remission, endoscopic response, endoscopic improvement, adverse events (AEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and infections. Ranking was assessed using the surface under the cumulative ranking curve (SUCRA) probabilities. Ritlecitinib exhibited the highest SUCRA probabilities for clinical remission (88.7%), clinical response (86.0%), and endoscopic improvement (92.1%). Upadacitinib exhibited superiority in endoscopic remission (85.6%) and response (99.5%), demonstrating moderate efficacy in clinical response (82.2%). A safety analysis revealed comparable AE rates for most agents compared to placebo, except for upadacitinib and brepocitinib. Tofacitinib showed the lowest risk of SAEs (72.3%). Upadacitinib had the lowest discontinuation rate (81.3%). Ivarmacitinib demonstrated optimal infection safety (80.3%). Upadacitinib has the best efficacy-safety profile for IBD, while ritlecitinib\u2019s superior efficacy is offset by higher safety risks. Long-term studies are needed to confirm these results.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024595343<\/jats:ext-link>\n                      , Identifier CRD42024595343.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1699928","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:25:45Z","timestamp":1769491545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Haidong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongci","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Head and Neck Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaxia","family":"Du","sequence":"additional","affiliation":[{"name":"Department of the Center of Gerontology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpu","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University","place":["Haikou, Hainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/ibd\/izab116","article-title":"Randomized controlled trial substudy of cell-specific mechanisms of janus kinase 1 inhibition with upadacitinib in the Crohn's Disease intestinal mucosa: analysis from the CELEST study","volume":"27","author":"Aguilar","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-022-00634-6","article-title":"Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment","volume":"19","author":"Bisgaard","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with Moderate-to-Severe, active, ulcerative colitis: a phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.cgh.2024.02.027","article-title":"Upadacitinib reduces Crohn's Disease symptoms within the first week of induction therapy","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/s0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of Janus kinase inhibitors in inflammatory bowel disease","volume":"11","author":"De Vries","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/s0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10067-022-06471-x","article-title":"JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know","volume":"42","author":"Evangelatos","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/s0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn's Disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41419-021-03702-y","article-title":"Bruton's tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response","volume":"12","author":"Guan","year":"2021","journal-title":"Cell Death Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/ecco-jcc\/jjad213","article-title":"Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis","volume":"18","author":"Hassan-Zahraee","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-med-052919-120048","article-title":"New therapeutics for ulcerative colitis","volume":"72","author":"Hirten","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/s0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1053\/j.gastro.2021.06.072","article-title":"Targeting of the Tec kinase ITK drives resolution of T cell-mediated colitis and emerges as potential therapeutic option in ulcerative colitis","volume":"161","author":"Lechner","year":"2021","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17474124.2022.2138857","article-title":"Filgotinib for moderately to severely active ulcerative colitis","volume":"16","author":"Mannucci","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/s0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/s0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"108402","DOI":"10.1016\/j.pharmthera.2023.108402","article-title":"Selective JAK1 inhibitors for the treatment of inflammatory bowel disease","volume":"245","author":"Nielsen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666x.2017.1291342","article-title":"JAK inhibition in inflammatory bowel disease","volume":"13","author":"Olivera","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"B33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjae003","article-title":"Efficacy and safety of filgotinib for the treatment of perianal fistulising crohn\u2019s disease [DIVERGENCE 2]: a phase 2, randomised, placebo-controlled trial","volume":"18","author":"Reinisch","year":"2024","journal-title":"J. Crohn's Colitis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"","journal-title":"Am. J. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","article-title":"Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: a prospective, open-label, randomized, pilot study","volume":"18","author":"Singh","year":"","journal-title":"J. Crohn's Colitis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/s0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s2468-1253(23)00208-x","article-title":"Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1177\/1756283x17727388","article-title":"Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges","volume":"10","author":"Vetter","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/gutjnl-2023-330002","article-title":"Early-life exposures and the microbiome: implications for IBD prevention","volume":"73","author":"Zhang","year":"2024","journal-title":"Gut"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:12:42Z","timestamp":1771924362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":53,"alternative-id":["10.3389\/fphar.2025.1699928"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1699928","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1699928"}}